Madrigal Pharma

$105.21 0.00% ($0.00)

Get ready to invest

About Madrigal Pharma

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Popular Stocks	Price	Change
AMC Entertainment AMC	$59.26 3.26%	3.26%
W ContextLogic WISH	$11.4 4.3%	4.3%
Apple AAPL	$130.46 0.54%	0.54%
C Clean Energy Fuels CLNE	$11.78 1.75%	1.75%
Bank of America BAC	$38.78 0.26%	0.26%
NIO NIO	$46.91 0.89%	0.89%
General Electric GE	$12.78 0%	0%
Ford F	$14.52 0.41%	0.41%
Palantir PLTR	$25.37 0.08%	0.08%
AT&T T	$28.65 0.17%	0.17%